Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 9,724 common shares with an aggregate market value of $312,986.38, to be sold through Fidelity Brokerage Services LLC on 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and were paid as compensation.
The filing also discloses prior sales by the same person, Paula Green, totaling 3,201 shares sold across five trades between 08/04/2025 and 10/02/2025, generating $86,859.32 in gross proceeds. The company-wide share count reported in the notice is 60,360,925 shares outstanding. The filer certifies no undisclosed material adverse information.
Notice of proposed insider sale: A Form 144 was filed for common stock of Twist Bioscience Corp (TWST) showing a proposed sale of 3,876 shares with an aggregate market value of 124,756.81, listing NASDAQ as the exchange and an approximate sale date of 10/06/2025. The shares were acquired on 10/01/2025 by restricted stock vesting as compensation from the issuer.
The filing lists prior open-market disposals by the same account (Dennis H. Cho) in the past three months totaling 2,026 shares sold across six trades between 08/04/2025 and 10/02/2025, producing gross proceeds shown per trade. The filer certifies no undisclosed material adverse information and includes the standard attestation language required by Rule 144.
Dennis Cho, Senior Vice President and Chief Legal Officer of Twist Bioscience Corporation (TWST), reported a sale of 124 shares of Common Stock on 10/02/2025. The transaction is described as a sell-to-cover executed to satisfy tax withholding on vested restricted stock units rather than a discretionary sale. The reported sale price was $29.161 per share and the reporting person retained 102,586 shares after the transaction. The form is signed by an attorney-in-fact and discloses the reporter's officer role.
Paula Green, who serves as SVP of Human Resources and a director at Twist Bioscience Corp (TWST), reported a mandated sell-to-cover transaction tied to the vesting of restricted stock units. On 10/02/2025 she disposed of 140 shares of common stock at $29.161 per share to satisfy tax withholding, leaving her with 124,402 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 10/06/2025.
The filing explicitly states the sale was not a discretionary trade but a company-mandated sale under the issuer's equity plan to cover tax obligations arising from RSU vesting. No options, warrants, or other derivative transactions are reported on this form.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corporation (TWST), reported a small non-discretionary sale of shares to cover tax withholding related to vested restricted stock units. The filing shows a sale of $29.161 per share for 476 shares on 10/02/2025, described as a mandatory "sell to cover" to satisfy tax withholding; these sales were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 632,560 shares of common stock.
The Form 4 also lists outstanding employee stock options and performance options with various exercise prices and vesting/exercise dates, including options exercisable immediately and a granted performance option that vested on 12/19/2022. The report was signed by an attorney-in-fact on 10/06/2025.
Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of $29.161-priced common stock on 10/02/2025. The Form 4 shows 206 shares were sold to satisfy tax withholding obligations tied to vested Restricted Stock Units; the filing states these were mandatory 'sell to cover' transactions rather than discretionary trades. Following the transaction and an administrative correction, the reporting person beneficially owns 232,482 shares. The Form 4 was filed by counsel on 10/06/2025 and is signed by an attorney-in-fact.
Twist Bioscience insider filings show a proposed sale under Rule 144 and multiple recent disposals of common stock. The notice reports an intended sale of 140 shares through Fidelity Brokerage Services with an approximate sale date of 10/02/2025 and an aggregate market value of $4,082.53. The shares were acquired on 10/01/2025 by restricted stock vesting and were paid as compensation. The filer also disclosed five prior sales by Paula Green between 07/02/2025 and 09/22/2025, totaling 3,203 shares and gross proceeds of $86,716.21. The filing records 60,360,925 shares outstanding for the issuer and includes the required attestation that no undisclosed material adverse information is known to the seller.
Form 144 notice for Twist Bioscience Corp (TWST) shows an officer or insider, Dennis H. Cho, proposing to sell 124 common shares on 10/02/2025. Those 124 shares were acquired the prior day, 10/01/2025, by restricted stock vesting as compensation. The filing lists the broker as Fidelity Brokerage Services LLC and indicates an aggregate market value of $3,615.95 for the shares to be sold. The issuer has 60,360,925 shares outstanding per the form. The filing also discloses six prior open-market sales by Dennis H. Cho from 07/02/2025 through 09/22/2025, totaling 2,027 shares and gross proceeds of $54,048.04 across those transactions. The filer certifies no undisclosed material adverse information.
TWST Form 144 summary: This notice reports proposed and recent sales of Twist Bioscience common stock by an individual identified as Patrick Finn. The filer proposes to sell 206 shares via Fidelity Brokerage with an aggregate market value of $6,007.15 and lists the company's outstanding share count as 60,360,925. The 206 shares were acquired on 10/01/2025 through restricted stock vesting and payment is listed as compensation. The filing also discloses four reported sales in the prior three months totaling 7,470 shares for $225,564.62. The signer represents they have no undisclosed material information about the issuer.
Form 144 notice for Twist Bioscience Corp (TWST): An insider submitted a Rule 144 notice to sell 476 shares of common stock on 10/02/2025 through Fidelity Brokerage Services on the NASDAQ. The filing reports the shares were acquired by restricted stock vesting on 10/01/2025 and were paid as compensation. The filing lists 60,360,925 shares outstanding and an aggregate market value for the 476 shares of $13,880.59. The document also discloses five prior sales by the same person between 07/02/2025 and 09/22/2025 totaling 12,766 shares with gross proceeds shown for each sale. The notice contains the required representation that the seller is not aware of undisclosed material adverse information about the issuer.